Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats

Colloids and Surfaces B: Biointerfaces

Volumn 115, Issue , 2014, Pages 286-294

  Gorain, Bapi ^a   Choudhury, Hira ^a   Kundu, Amit ^a   Sarkar, Lipi ^a   Karmakar, Sanmoy ^a   Jaisankar, P ^b   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Bioavailability; Caco 2 permeability; Hypertensive model; Nanoemulsion; Olmesartan medoxomil

Indexed keywords

ANTI-HYPERTENSIVE ACTIVITIES; BIOAVAILABILITY; CACO-2 PERMEABILITY; NANOEMULSION; OLMESARTAN MEDOXOMIL; PHARMACOKINETIC PROFILES; PHARMACOKINETIC STUDIES; THERMODYNAMICALLY STABLE;

BIOCHEMISTRY; DROPS; PHARMACOKINETICS;

DRUG PRODUCTS;

OLMESARTAN; SOYBEAN OIL; ANTIHYPERTENSIVE AGENT; EMULSION; IMIDAZOLE DERIVATIVE; NANOPARTICLE; TETRAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; ELECTRIC CONDUCTIVITY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PH; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; REFRACTION INDEX; STOMACH JUICE; SUSTAINED DRUG RELEASE; THERMODYNAMICS; THERMOSTABILITY; VALIDATION STUDY; VISCOSITY; ZETA POTENTIAL; ABSORPTION; ANIMAL; BLOOD PRESSURE; CACO 2 CELL LINE; DRUG EFFECTS; EMULSION; HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; REFRACTOMETRY; STATIC ELECTRICITY; ULTRASTRUCTURE; WISTAR RAT;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; ELECTRIC CONDUCTIVITY; EMULSIONS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERTENSION; IMIDAZOLES; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; REFRACTOMETRY; STATIC ELECTRICITY; TETRAZOLES; THERMODYNAMICS; VISCOSITY;

EID: 84891452160     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.12.016     Document Type: Article

References (46)

1. Gursoy R.N., Benita S. Biomed. Pharmacother. 2004, 58:173.
2. Porter C.J., Pouton C.W., Cuine J.F., Charman W.N. Adv. Drug Deliv. Rev. 2008, 60:673.
3. Date A.A., Desai N., Dixit R., Nagarsenker M. Nanomedicine 2010, 5:1595.
4. Kotta S., Khan A.W., Pramod K., Ansari S.H., Sharma R.K., Ali J. Expert Opin. Drug Deliv. 2012, 9(5):585.
5. Bali V., Ali M., Ali J. Int. J. Pharm. 2011, 403:46.
6. Shafiq S., Shakeel F., Talegaonkar S., Ahmad F.J., Khar R.K., Ali M. Eur. J. Pharm. Biopharm. 2007, 66:227.
7. Parveen R., Baboota S., Ali J., Ahuja A., Vasudev S.S., Ahmed S. Int. J. Pharm. 2011, 413:245.
8. Gao F., Zhang Z., Bu H., Huang Y., Gao Z., Shen J. J. Control. Release 2011, 149:168.
9. Anton N., Beniot J.P., Saulnier P. J. Control. Release 2008, 128:185.
10. Singh S., Pathak K., Bali V. AAPS PharmSciTech 2012, 13(4):1212.
11. Koike H., Konse T., Sada T., Ikeda T., Hyogo S., Hinman D., Saito H., Yanagisawa H. Annu. Rep. Sankyo Res. Lab. 2003, 55:1.
12. Norwood D., Branch E., Smith B., Honeywell M. Drug Forecast 2002, 27(12):611.
13. Yanagisawa H., Amemiya Y., Kanazaki T., Shimoji Y., Fujimoto K., Kitahara Y., Sada T., Mizuno M., Ikeda M., Miyamoto S., Furukawa Y., Koike H. J. Med. Chem. 1996, 39(1):323.
14. Kobayashi N., Fugimori I., Watanabe M., Ikeda T. Anal. Biochem. 2000, 287:272.
15. Yamada A., Maeda K., Kamiyama E., Sugiyama D., Kondo T., Shiroyanagi Y., Nakazawa H., Okano T., Adachi M., Schuetz J.D., Adachi Y., Hu Z., Kusuhara H., Sugiyama Y. Drug Metab. Dispos. 2007, 35(12):2166.
16. Klaus O., Stumpe M.D. Clin. Ther. 2004, 26:A33.
17. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., Smith R.D. Pharmacol. Rev. 1993, 45:205.
18. Oparil S., Melino M., Lee J., Fernandez V., Heyrman R. Clin. Ther. 2010, 32:1252.
19. Ram C.V., Sachson R., Littlejohn T., Qian C., Shojaee A., Stoakes K.A., Neutel J.M. Am. J. Cardiol. 2011, 107:1346.
20. Nakagomi-Hagihara R., Nakai D., Kawai K., Yoshigae Y., Tokui T., Abe T. Drug Metab. Dispos. 2006, 34:862.
21. Lee B.S., Kang M.J., Choi W.S., Choi Y.B., Kim H.S., Lee S.K., Lee J., Choi Y.W. Arch. Pharm. Res. 2009, 32(11):1629.
22. FDA Drug Safety Communication, FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM359496.pdf.
23. Ferguson A., MacDonald T.T. Ciba Found. Symp. 1977, 46:305.
24. Gorain B., Choudhury H., Biswas E., Barik A., Jaaisankar P., Pal T.K. RSC Adv. 2013, 3:10887.
25. Ragelle H., Crauste-Manciet S., Seguin J., Brossard D., Scherman D., Arnaud P., Chabot G.G. Int. J. Pharm. 2012, 427:452.
26. Pouton C.W. Adv. Drug Deliv. Rev. 1997, 25:47.
27. Khoo S.M., Humberstone A.J., Porter C.J.H., Edwards G.A., Charman W.N. Int. J. Pharm. 1998, 167:155.
28. Hidalgo I.J., Raub T.J., Borchardt R.T. Gastroenterology 1989, 96:736.
29. Volpe D.A., Asafu-Adjaye E.B., Ellison C.D., Doddapaneni S., Uppoor R.S., Khan M.A. AAPS J. 2008, 10(2):360.
30. Food and Drug Administration of the United States Guidance for Industry Bioanalytical Method Validation 2001, May, (accessed 12.11.11). http://www.fda.gov/cder/guidance/index.html.
31. Choudhury H., Gorain B., Das A., Ghosh B., Pal T.K. Curr. Anal. Chem. 2013, 10.2174/1573411010999131129102723.
32. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. AAPS J. 2007, 9(1). (article 4).
33. Bansal S., DeStefano A. AAPS J. 2007, 9(1):E109. (article 11).
34. Nandi U., Karmakar S., Das A.K., Ghosh B., Padman A., Chatterjee N., Pal T.K. Regul. Toxicol. Pharm. 2013, 65:68.
35. Bahgat A., Aziz H.A., Raafat M., Mahdy A., Khatib A., Ismail A., Khayyal T.M. Fundam. Clin. Pharmacol. 2008, 22:693.
36. Johnson R.A., Freeman R.H. Am. J. Hypertens. 1992, 5(2):919.
37. Vyas S.P., Khar R.K. Targeted and Controlled Drug Delivery: Novel Carrier Systems 2002, 280-302. CBS Publishers, New Delhi.
38. Azeem A., Rizwan M., Ahmad F.Z., Iqbal Z., Khar R.K., Aqil M., Talengaonkar S. AAPS PharmSciTech 2009, 10(1):69.
39. Bali V., Ali M., Ali M.J. J. Drug Target. 2010, 18(7):506.
40. Lovelyn C., Attama A.A. J. Biomater. Nanobiotechnol. 2011, 2:626.
41. Li X., Anton N., Ta T.M.C., Zhao M., Messaddeq N., Vandamme T.F. Int. J. Nanomed. 2011, 6:1313.
42. Kakumanu S., Tagne J.B., Wilson T.A., Nicolosi R.J. Nanomedicine: NBM 2011, 7:277.
43. Lockman R.R., Koziara J.M., Mumper R.J., Allen D.D. J. Drug Target. 2004, 12:635.
44. Lockman P.R., Mumper R.J., Khan M.A., Allen D.D. Ind. Pharm. 2002, 28:1.
45. Palmer R.M.J., Ferrige A.G., Moncada S. Nature 1987, 327:524.
46. Salazar F.J., Pinilla J.M., Alberola A., Romero J.C. Hypertension 1991, 18:387.